Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease (Feb 2024)

High Prevalence of New Clinically Significant Findings in Patients With Embolic Stroke of Unknown Source Evaluated by Cardiac Magnetic Resonance Imaging

  • Irum D. Kotadia,
  • Robert O'Dowling,
  • Akosua Aboagye,
  • Richard J. Crawley,
  • Neil Bodagh,
  • Ali Gharaviri,
  • Daniel O'Hare,
  • Jose Alonso Solis‐Lemus,
  • Caroline H. Roney,
  • Iain Sim,
  • Deborah Ramsey,
  • David Newby,
  • Amedeo Chiribiri,
  • Sven Plein,
  • Laszlo Sztriha,
  • Paul Scott,
  • Pier‐Giorgio Masci,
  • James Harrison,
  • Michelle C. Williams,
  • Jonathan Birns,
  • Peter Somerville,
  • Ajay Bhalla,
  • Steven Niederer,
  • Mark O'Neill,
  • Steven E. Williams

DOI
https://doi.org/10.1161/JAHA.123.031489
Journal volume & issue
Vol. 13, no. 3

Abstract

Read online

Background Embolic stroke of unknown source (ESUS) accounts for 1 in 6 ischemic strokes. Current guidelines do not recommend routine cardiac magnetic resonance (CMR) imaging in ESUS, and beyond the identification of cardioembolic sources, there are no data assessing new clinical findings from CMR in ESUS. This study aimed to assess the prevalence of new cardiac and noncardiac findings and to determine their impact on clinical care in patients with ESUS. Methods and Results In this prospective, multicenter, observational study, CMR imaging was performed within 3 months of ESUS. All scans were reported according to standard clinical practice. A new clinical finding was defined as one not previously identified through prior clinical evaluation. A clinically significant finding was defined as one resulting in further investigation, follow‐up, or treatment. A change in patient care was defined as initiation of medical, interventional, surgical, or palliative care. From 102 patients recruited, 96 underwent CMR imaging. One or more new clinical findings were observed in 59 patients (61%). New findings were clinically significant in 48 (81%) of these patients. Of 40 patients with a new clinically significant cardiac finding, 21 (53%) experienced a change in care (medical therapy, n=15; interventional/surgical procedure, n=6). In 12 patients with a new clinically significant extracardiac finding, 6 (50%) experienced a change in care (medical therapy, n=4; palliative care, n=2). Conclusions CMR imaging identifies new clinically significant cardiac and noncardiac findings in half of patients with recent ESUS. Advanced cardiovascular screening should be considered in patients with ESUS. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT04555538.

Keywords